Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)

Journal of Pediatrics

Volumn 144, Issue 5, 2004, Pages 574-580

  Harmatz, Paul ^a   Whitley, Chester B ^b   Waber, Lewis ^b   Pais, Ray ^b   Steiner, Robert ^b   Plecko, Barbara ^b   Kaplan, Paige ^b   Simon, Julie ^b   Butensky, Ellen ^b   Hopwood, John J ^b  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GALSULFASE; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ADOLESCENT; ANGIONEUROTIC EDEMA; ARTICLE; AUDITORY TUBE DYSFUNCTION; CARPAL TUNNEL SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; COLON ADENOCARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ENZYME REPLACEMENT; FATTY ACID DESATURATION; FEMALE; GLIOMA; HUMAN; HYPOTENSION; INFUSION; INJECTION PAIN; JOINT MOBILITY; LABORATORY TEST; LETHARGY; MALE; MAROTEAUX LAMY SYNDROME; NECK PAIN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SHOULDER; SIDE EFFECT; SKIN IRRITATION; SYNCOPE; TACHYPNEA; THORAX PAIN; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; URINALYSIS; URTICARIA; WALKING;

EID: 1542669902     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2004.03.018     Document Type: Article

References (23)

1. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver C, Beaudet AL, Sly WS, et al, editors. The metabolic basis of inherited disease. New York: McGraw-Hill; 1995. p. 2465-93.
2. Lowry RB, Applegarth DA, Toone JR, MacDonald E, Thunem NY. An update on the frequency of mucopolysaccharide syndromes in British Columbia. Hum Genet 1990;85:389-90.
3. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-54.
4. Nelson J. Incidence of the mucopolysaccharidoses in Northern Ireland. Hum Genet 1997;101:355-8.
5. Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, doJong JG, van Weely S, et al. The frequency of lysosomal storage diseases in the Netherlands. Hum Genet 1999;105:151-6.
6. Krivit W, Pierpont ME, Ayaz K, Tsai M, Ramsay NK, Kersey JH, et al. Bone-marrow transplantation in the Maroteaux-Lamy syndrome (mucopolysaccharidosis Type VI). Biochemical and clinical status 24 months after transplantation. N Engl J Med 1984;311:1606-11.
7. Krivit W. Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Treatment by allogeneic bone marrow transplantation in 6 patients and potential for autotransplantation bone marrow gene insertion. Int Pediatr 1992;7:47-52.
8. Hoogerbrugge PM, Brouwer OF, Bordigoni P, The European Group for Transplantation. Allogeneic bone marrow transplantation for lysosomal storage diseases. Lancet 1995;246:1398-402.
9. Wraith JE. Advances in the treatment of lysosomal storage disease. Dev Med Child Neurol 2001;43:639-46.
10. Bielicki J, Crawley AC, Davey RCA, Varnai JC, Hopwood JJ. Advantages of using same species enzyme for replacement therapy in a feline model of mucopolysaccharidosis type VI. J Biol Chem 1999;274: 36335-43.
11. Crawley AC, Brooks DA, Muller VJ, Petersen BA, Isaac EL, Bielicki J, et al. Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome. J Clin Invest 1996;97:1864-73.
12. Whitley CB, Ridnour MD, Draper KA, Dutton CM, Neglia JP. Diagnostic test for mucopolysaccharidosis I. Direct method for quantifying excessive urinary glycosaminoglycan excretion. Clin Chem 1989;35:374-9.
13. Nixon PA, Joswiak ML, Fricker FJ. A six-minute walk test for assessing exercise tolerance in severely ill children. J Pediatr 1996;129:362-6.
14. Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arth Rheum 1994;37:1761-9.
15. Sperhac AM, Salzer JL. A new developmental screening test. The Denver II. J Am Acad Nurse Pract 1991;3:152-7.
16. Byers S, Auclair D, Brumfield LK, Robinson A, Hopwood JJ. Localised therapy for joint disease in MPS VI. 2002. Paris, 7th International Symposium on MPS and Related Diseases. 6-20-2002.
17. Simonaro CM, Haskins ME, Schuchman EH. Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab Invest 2001;81:1319-28.
18. Rosenberg M, Kingma W, Fitzpatrick MA, Richards SM. Immunosurveillance of alglucerase enzyme therapy for gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood 1999;93:2081-8.
19. Crawley AC, Niedzielski KH, Isaac EL, Davey RCA, Byers S, Hopwood JJ. Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI. J Clin Invest 1997;99:651-62.
20. Meikle PJ, Ranieri E, Ravenscroft EM, Hua CT, Brooks DA, Hopwood JJ. Newborn screening for lysosomal storage disorders. Southeast Asian J Trop Med Public Health 1999;30:104-10.
21. Whitley CB, Draper KA, Dutton CM, Brown PA, Severson SL, France LA. Diagnostic test for mucopolysaccharidosis II. Rapid quantification of glycosaminoglycan in urine samples collected on a paper matrix. Clin Chem 1989;35:2074-81.
22. Whitley CB, Spielman RC, Herro G, Severson ST. Urinary glycosaminoglycan excretion quantified by an automated semimicro method in specimens conveniently transported from around the globe. Mol Genet Metabol 2002;75:56-64.
23. Wraith JE. Enzyme replacement therapy in mucopolysaccharidosis type I: progress and emerging difficulties. J Inherit Metab Dis 2001;24:245-50.